Table 1 Patient demographics and tumour characteristics

No. of patients

32(11%)

249(89%)

Age(IQR, range)

65(19,38–92)

67(12,21–95)

0.116

Sex

0.341

 Male

16(50%)

149(60%)

 Female

16(50%)

100(40%)

Tumour location

0.001

 Right

22(69%)

90(36%)

 Left

10(31%)

159(64%)

Differentiation grade

 < 0.001***

 High

1(3%)

8(3%)

 Moderate

10(35%)

200(80%)

 Low

7(24%)

27(11%)

 Mucinous adenocarcinoma

11(38%)

14(6%)

Mucinous component, MC

 < 0.001

 Yes

16(50%)

33(13%)

 No

16(50%)

216(87%)

T stage

0.958***

 T1

0

7(3%)

 T2

3(9%)

24(9%)

 T3

25(78%)

179(72%)

 T4

4(13%)

39(16%)

N stage

0.013***

 N0

25(78%)

143(57%)

 N1 + N2

7(22%)

106(43%)

M stage

1.000**

 M0

30(94%)

230(92%)

 M1

2(6%)

19(8%)

Stage

0.319***

 I

3(9%)

28(11%)

 II

20(63%)

112(45%)

 III

7(22%)

90(36%)

 IV

2(6%)

19(8%)

Perineural invasion, PI

0.216

 Positive

6(19%)

77(31%)

 Negative

26(81%)

172(69%)

Lympho-vascular invasion, LVI

0.341

 Positive

10(31%)

102(41%)

 Negative

22(69%)

147(59%)

Peritoneal metastasis, PM

1.0**

 Positive

1(3%)

9(4%)

 Negative

31(97%)

240(96%)

Tumour deposit, TD

1.0**

 Positive

3(9%)

26(10%)

 Negative

29(91%)

223(90%)

Pre-surgical serum tumour marker(IQR, range)

 CEA(ng/ml)

2.06(2.64,0.35–60)

2.81(8.65,0.2–300.0)

0.110

 AFP(ng/ml)

1.76(1.15,1.00–16.00)

1.77(1.83,1.00–19.40)

0.724

 CA125, (U/ml)^a

5.65(7.88,3.00–76.10)

5.01(4.90,2.00–114.90)

0.344

 CA153, (U/ml)^b

3.83(1.07,3.59–17.76)

3.89(1.55,3.50–54.74)

0.328

 CA199, (U/ml)^c

11.14(17.38,3.50–305.47)

11.06(18.71,1.91–467.31)

0.931

 CA242, (U/ml)^d

3.69(8.35,1.00–172.07)

3.57(6.26,1.00–200.00)

0.805

CEA status

0.014

 Positive

4(12%)

85(34%)

 Negative

28(88%)

164(66%)

No. of lymph node metastasis (IQR, range)

0(0,0–2)

0(2,0–21)

0.008

LN yields (IQR, range)

20(15.75,9–55)

20(14,2–64)

0.071

LN metastasis ratio (IQR, range)

0(0,0–0.1)

0(0.1,0–1)

0.003

Tumour long axes in the gross specimen(cm) (IQR, range)

6.75(3.88,2.5–11.5)

4.50(2.50,1.0–12.0)

 < 0.001

Tumour short axes in the gross specimen(cm) (IQR, range)

5.00(2.38,1.5–9.0)

3.50(2.00,0.9–9.0)

 < 0.001

Maximum tumour area(cm²) (IQR, range)

34.88(32.83,4.5–103.5)

15.20(16.00,1.0–108.0)

 < 0.001